Andy Hahn, MD
An ongoing phase III study could answer the question of whether abiraterone acetate (Zytiga) added to docetaxel is more effective for patients with metastatic hormone-sensitive prostate cancer than treating patients without the androgen receptor (AR) inhibitor.
The multicenter, multi-arm PEACE1 trial is studying the benefit of docetaxel plus androgen deprivation therapy (ADT), with or without abiraterone and prednisone, and with or without radiotherapy (NCT01957436). The study has an estimated enrollment of 1168 patients and an estimated primary completion date of October 2018.
... to read the full story